Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maurizio Pompili and Francesca Ponziani.
Maurizio Pompili
Connection Strength
9.227
Francesca Ponziani
  1. NAFLD or comorbidities, that is the question. J Hepatol. 2020 09; 73(3):723.
    View in: PubMed
    Score: 0.878
  2. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919848184.
    View in: PubMed
    Score: 0.822
  3. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2018 12; 48(11-12):1301-1311.
    View in: PubMed
    Score: 0.792
  4. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018 Jul; 12(7):641-656.
    View in: PubMed
    Score: 0.771
  5. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol. 2017 Dec 28; 9(36):1322-1331.
    View in: PubMed
    Score: 0.748
  6. Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma. J Hepatol. 2017 Sep 21.
    View in: PubMed
    Score: 0.734
  7. Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. Liver Int. 2017 08; 37(8):1251.
    View in: PubMed
    Score: 0.710
  8. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Am J Kidney Dis. 2017 Aug; 70(2):297-300.
    View in: PubMed
    Score: 0.706
  9. Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Dig Liver Dis. 2021 05; 53(5):541-544.
    View in: PubMed
    Score: 0.233
  10. Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. Gastroenterology. 2021 04; 160(5):1891-1893.
    View in: PubMed
    Score: 0.230
  11. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020 12; 24(24):13072-13088.
    View in: PubMed
    Score: 0.229
  12. Letter: liver involvement and mortality in COVID-19 patients - authors' reply. Aliment Pharmacol Ther. 2020 Oct; 52(7):1264-1265.
    View in: PubMed
    Score: 0.226
  13. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment Pharmacol Ther. 2020 09; 52(6):1060-1068.
    View in: PubMed
    Score: 0.224
  14. Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. Sci Rep. 2019 10 25; 9(1):15373.
    View in: PubMed
    Score: 0.212
  15. Low molecular weight heparin as cause of liver injury: case report and literature review. Eur Rev Med Pharmacol Sci. 2019 Sep; 23(17):7649-7654.
    View in: PubMed
    Score: 0.210
  16. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection. 2019 Apr; 47(2):313-316.
    View in: PubMed
    Score: 0.198
  17. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology. 2019 01; 69(1):107-120.
    View in: PubMed
    Score: 0.194
  18. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol. 2018 May; 11(5):519-524.
    View in: PubMed
    Score: 0.190
  19. Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? Dig Dis Sci. 2017 09; 62(9):2220-2222.
    View in: PubMed
    Score: 0.183
  20. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017 Jul 07; 23(25):4491-4499.
    View in: PubMed
    Score: 0.181
  21. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017 Mar 08; 9(7):352-367.
    View in: PubMed
    Score: 0.177
  22. Post-liver transplant intrahepatic cholestasis: etiology, clinical presentation, therapy. Eur Rev Med Pharmacol Sci. 2017 03; 21(1 Suppl):23-36.
    View in: PubMed
    Score: 0.177
  23. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (= 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. Eur Rev Med Pharmacol Sci. 2019 Sep; 23(18):7786-7801.
    View in: PubMed
    Score: 0.053
  24. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? Eur J Radiol. 2019 May; 114:32-37.
    View in: PubMed
    Score: 0.051
  25. Bile Collection Detected With BrIDA Scintigraphy in a Patient With Hepatocellular Carcinoma. Clin Nucl Med. 2018 Nov; 43(11):823-824.
    View in: PubMed
    Score: 0.050
  26. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2018 12; 25(12):1493-1500.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.